Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 220 (planned)
- Started
- May 20, 2024
- Main results expected
- Jan 15, 2029
- Fully finished
- Jan 15, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants who experience one or more dose-limiting toxicities (DLTs)
Measured over: Up to approximately 28 days
Number of participants who experience one or more adverse events (AEs)
Measured over: Up to approximately 46 months
Number of participants who discontinue study intervention due to an AE
Measured over: Up to approximately 46 months
Prostate-specific antigen (PSA) response rate
Measured over: Up to approximately 46 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06353386 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC